Drug or intervention
Bendamustine Clinical Trials
Studies that test Bendamustine, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 61B-cell Lymphoma
Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.
Bendamustine and the combination of fludarabine/cyclophosphamide are fully authorized chemotherapy agents in Switzerland for lymphoma treatment and currently used in routine clinical practice as lymphodepletion strategy before…
- Trial name
- FC-BALANCE (NCT07593482)
- Testing
- bendamustine hydrochloride, Cyclophosphamide, Fludarabine
- Where
- 9 sites in Switzerland
- Volunteers
- 92 people
- Sponsor
- Swiss Cancer Institute
Follicular Lymphoma
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy.
- Trial name
- NCT07634471
- Testing
- MK-1045, Rituximab, Rituximab biosimilar
- Where
- 35 sites in United States, Argentina and 11 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM).
- Trial name
- Prime REMIX (NCT07725406)
- Testing
- Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Weill Medical College of Cornell University
DLBCL, Diffuse Large B-Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the…
- Trial name
- NCT05139017
- Testing
- Zilovertamab vedotin, Rituximab, Gemcitabine
- Where
- 135 sites in United States, Argentina and 24 more
- Volunteers
- 290 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer, Pancreas Cancer
T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
This phase I trial studies the side effects and best dose of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRASG12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) and to see how well they work in…
- Conditions
- Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
- Trial name
- NCT06043713
- Testing
- Bendamustine, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed…
- Trial name
- GLOBRYTE (NCT06084936)
- Testing
- Obinutuzumab, Glofitamab, Rituximab
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma (FL)
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL).
- Trial name
- OLYMPIA-1 (NCT06091254)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 190 sites in United States, Australia and 17 more
- Volunteers
- 822 people
- Sponsor
- Regeneron Pharmaceuticals
CLL, Chronic Lymphocytic Leukemia
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab…
- Trial name
- CaDAnCe-302 (NCT06846671)
- Testing
- Tacabrutideg, Bendamustine, Idelalisib
- Where
- 132 sites in United States, Argentina and 12 more
- Volunteers
- 250 people
- Sponsor
- BeOne Medicines
Peripheral T Cell Lymphoma
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma.
- Trial name
- NCT04083495
- Testing
- ATLCAR.CD30 T cells, Bendamustine, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS.
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- IMPACT-MS (NCT07477639)
- Testing
- TRX319, Bendamustine
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
Completed, with results posted
All –Chronic Lymphocytic Leukemia
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
The purpose of this study is to determine the efficacy of bendamustine and rituximab (BR) followed by venetoclax for 12 months. The total time on therapy is 15 months.
- Trial name
- NCT03609593
- Testing
- Bendamustine, Venetoclax, Rituximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Nicole Lamanna
Hodgkin Lymphoma
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth).
- Trial name
- NCT05508867
- Testing
- favezelimab/pembrolizumab, bendamustine, gemcitabine
- Where
- 105 sites in United States, Argentina and 18 more
- Volunteers
- 203 people
- Sponsor
- Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
This is a phase 1/2 multicenter study to assess the safety and effectiveness of brentuximab vedotin and bendamustine, when given together, in patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma (ALCL) that has either…
- Trial name
- SGN+Benda (NCT01657331)
- Testing
- Brentuximab Vedotin, Bendamustine, Neulasta
- Where
- 3 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Columbia University
Marginal Zone B-cell Lymphoma
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).
- Trial name
- NCT02433795
- Testing
- bendamustine plus rituximab
- Where
- 11 sites in South Korea
- Volunteers
- 27 people
- Sponsor
- Seoul National University Hospital
Mantle Cell Lymphoma
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
This study is designed to evaluate the efficacy and safety of acalabrutinib plus bendamustine and rituximab followed by acalabrutinib plus cytarabine and rituximab in subjects with treatment naïve mantle cell lymphoma (MCL), as a…
- Trial name
- NCT03623373
- Testing
- Bendamustine, Rituximab, Acalabrutinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine